GSK-5471713 / GSK - LARVOL DELTA

First-time-in-human Phase 1/2 study of GSK5471713, an androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2026) - No abstract available

Clinical • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

GSK5471713: A novel, selective oral androgen receptor degrader with best-in-class potential for the treatment of prostate cancer (AACR 2026) - "Patients with locally advanced or metastatic disease are frequently treated with AR pathway inhibitors (ARPIs) targeting AR (e.g., enzalutamide) and/or androgen synthesis (e.g., abiraterone), and while these therapies offer survival benefit, patients frequently develop resistance via reactivation of AR signaling. In total, these data demonstrate GSK5471713 as a potential best-in-class AR degrader offering benefit to patients with prostate cancer. GSK5471713 is expected to advance into Phase 1 clinical studies in early 2026."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • CRBN

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor